

Cover Story
Conversation with The Cancer Letter
On Dec. 3, the faculty and staff members at the OHSU Knight Cancer Institute received an email from Brian J. Druker, the institution’s star scientist, former director, and current CEO, informing them that he would be stepping down from his executive role.
By Yiqing Wang
In Brief


Clinical Roundup
Drugs & Targets


NCI Trials


NCI Trials for December 2024
The National Cancer Institute approved the following clinical research studies last month.
Trending Stories
- Mt. Sinai forms committee to probe Epstein links to breast center founder Eva Dubin, other faculty members
- CBER Director Vinay Prasad dared to “say no to drugs”
- One result, two reactions: GRAIL’s Hall and NCI’s Castle react to negative NHS-Galleri trial outcome
- Hoping to hit a $200M target, NCI and FNIH develop a plan for advancing cancer vaccines
NCI Director Letai: “How aggressive can we be?” - Vinay Prasad, oncology’s gadfly-turned-CBER-director, will leave FDA (again)
- A new working group will conduct site visits and advise NCAB and NCI director on cancer center grants
















